","image":{"@type":"ImageObject","url":"http://g.foolcdn.com/avatar/1706180953/large.ashx","height":"80","width":"80"}},"about":[{"@type":"Corporation","tickerSymbol":"NYSE TEVA"},{"@type":"Corporation","tickerSymbol":"NASDAQ BIIB"}],"publisher":{"@type":"Organization","@id":"https://www.fool.com/","name":"The Motley Fool","url":"https://www.fool.com/","logo":{"@type":"ImageObject","url":"https://g.foolcdn.com/misc-assets/logo-tmf-primary-7-magenta-royalpurple.svg","width":"157","height":"43"},"brand":"The Motley Fool","contactPoint":{"@type":"ContactPoint","contactType":"Media Inquiries","email":"
[email protected]"},"publishingPrinciples":"https://www.fool.com/about/","sameAs":["https://www.fool.com/about/","https://en.wikipedia.org/wiki/The_Motley_Fool","https://www.wikidata.org/wiki/Q7752442","https://www.linkedin.com/company/the-motley-fool","https://www.facebook.com/themotleyfool/","https://x.com/themotleyfool","https://www.instagram.com/themotleyfoolofficial/","https://www.youtube.com/channel/UCpRQuynBX9Qy9tPrcswpPag","https://www.pinterest.com/themotleyfool/","https://www.tiktok.com/@themotleyfoolofficial","https://www.google.com/search?kgmid=/m/0578mk"]},"description":"Teva Pharmaceuticals is down 8% today, but it's not directly due to competition in the multiple sclerosis space from new drugs like Biogen's Tecfidera. To find out what happened and what may lie ahead for Teva, watch this video.","image":{"@type":"ImageObject","height":"630","width":"1200"}}","image":{"@type":"ImageObject","url":"http://g.foolcdn.com/avatar/1706180953/large.ashx","height":"80","width":"80"}},"inLanguage":"en-US"}
Down 8%: What's Behind Teva's Massive Plunge?
Teva Pharmaceuticals is down 8% today, but it's not directly due to competition in the multiple sclerosis space from new drugs like Biogen's Tecfidera. To find out what happened and what may lie ahead for Teva, watch this video.
